ArticleUrologia internationalis2018
The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1.
Article in Urologia internationalis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinicopathologic predictors of outcomes in children with stage I testicular germ cell tumors: A pooled post hoc analysis of trials from the Children's Oncology Group.Journal of pediatric urology · 2022Pooled it
- Diagnostic performance of microRNAs in testicular germ cell tumors: a systematic review and meta-analysis.Aging · 2021Pooled it
- Rapid Clearance of microRNA-371a-3p: A Longitudinal Study of Serum Levels in Patients with Localized Testicular Germ Cell Tumors.European urology open science · 2026Article
- Potential next generation markers of testicular germ cell tumors: miRNA-371a-3p.International urology and nephrology · 2025Review
- Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours.Journal of cancer research and clinical oncology · 2025Article
- Matching plasma and tissue miRNA expression analysis to detect viable ovarian germ cell tumors.PloS one · 2025Article
- Current and Evolving Biomarkers in the Diagnosis and Management of Testicular Germ Cell Tumors.Journal of clinical medicine · 2024Review
- Perioperative Serum MicroRNA 371a-3p and 372-3p Levels in Patients with Clinically Localized Testicular Masses.European urology open science · 2024Article
- New insights on testicular cancer prevalence with novel diagnostic biomarkers and therapeutic approaches.Cancer reports (Hoboken, N.J.) · 2024Review
- Review
- Epigenetic Factors and ncRNAs in Testicular Cancer.International journal of molecular sciences · 2023Review
- Biomarkers of disease recurrence in stage I testicular germ cell tumours.Nature reviews. Urology · 2022Review
- Analytical Validation and Performance Characteristics of Molecular Serum Biomarkers, miR-371a-3p and miR-372-3p, for Male Germ Cell Tumors, in a Clinical Laboratory Setting.The Journal of molecular diagnostics : JMD · 2022Article
- Emerging Role of Biomarkers in Testicular Germ Cell Tumors.Current oncology reports · 2022Review
- Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1.World journal of urology · 2022Article
- DigiMir Test: Establishing a Novel Pipeline for MiR-371a Quantification Using Droplet Digital PCR in Liquid Biopsies From Testicular Germ Cell Tumor Patients.Frontiers in oncology · 2022Article
- Referring to the article published on pp. 400-406 of this issue: Progress and challenges in testicular cancer microRNAs.Asian journal of urology · 2021Article
- Narrative review of developing new biomarkers for decision making in advanced testis cancer.Translational andrology and urology · 2021Review
- Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study.Scientific reports · 2021Article
- The Road Ahead for Circulating microRNAs in Diagnosis and Management of Testicular Germ Cell Tumors.Molecular diagnosis & therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccumulating evidence suggests serum levels of microRNA (miR)-371a-3p to be a novel tumour marker of testicular germ cell tumours (GCTs). Presently, there is only limited information regarding the velocity of decline of serum levels in response to treatment. PATIENTS AND
methodsTwenty-four patients with testicular GCT (20 seminoma, 4 nonseminoma, median age 40 years) with clinical stage 1 had measurements of serum levels of miR-371a-3p preoperatively and repeatedly on the following 3 days. Three had additional tests done within 24 h after surgery. Measurement results were analysed using descriptive statistical methods.
resultsSerum levels dropped to 2.62, 1.27, and 0.47% of the preoperative level within 1, 2, and 3 days, respectively. The computed half-life amounts to 3.7-7 h. The velocity of decay is significantly associated with tumour size.
conclusionsSerum-levels of miR-371a-3p have a short half-life of less than 12 h. The rapid decay after treatment represents a valuable feature confirming the usefulness of miR-371a-3p as a valuable serum biomarker of GCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.